Jan 28, 2013 03:00 EST SwedenBIO SwedenBIO, along with its sister organizations in Denmark, Finland and Norway – Biopeople, the Finnish and Norwegian BioIndustry Associations – invites you to an international partner and investor meeting. The Nordic Life Science Days (former Life Science Investment Day Scandinavia) will take place at Stockholm Waterfront on Oct 14 to 15, 2013
Dec 20, 2012 17:18 EST BioNavis Ltd In 2012, BioNavis Ltd secured five times higher instrument order intake than in 2011. While many companies are forced to restructure their operations, BioNavis has hired several professionals with deep understanding of the technology and its applications in the UK, USA, China, Germany and Finland, effectively doubling the amount of personnel in the company.
May 02, 2012 17:40 EDT BioNavis Ltd BioNavis Ltd. announces the winners of the International Multi-Parametric Surface Plasmon Resonance (MP-SPR) Contest. The winning proposals from New Zealand and from Poland are both based on assessing new types of active polymers. The applications of such smart polymers include solar, biosensors, smart implants, drug delivery, and toxicology for instance.
Jan 31, 2012 06:06 EST BioNavis Ltd Traditional surface plasmon resonance (SPR) has been used in drug discovery for more than 20 years. Now, with BioNavis SPR Navi 200 and SPR Navi 220A instruments, SPR phenomena can be used also in biophysics, biomaterials, and biosensor development. Furthermore, SAMP-SPR by BioNavis and Episentec enhances the capabilities of the SPR technology increasing its sensitivity and specificity 100-fold!
Mar 21, 2011 01:30 EDT P.U.L.S. AB LIDDS new local treatment of prostate cancer shows a clear local antiandrogen response and is well tolerated. The Swedish pharmaceutical company presented interim data from its phase IIa trial at the 26th Annual Congress of the European Association of Urology (EAU) in Vienna this weekend.
Mar 02, 2011 00:30 EST P.U.L.S. AB A new molecule has been discovered by virus researchers at Umeå University. This important discovery was recently published in the well respected journal Nature Medicine. The molecule is essential to the virus that causes the serious eye disease epidemic keratoconjunctivitis (EKC). Currently, there is no approved therapy to treat this highly contagious eye infection.